Summary:
- Y-mAbs Therapeutics faces a downgrade, impacting its stock value.
- Analysts predict significant potential upside despite current challenges.
- Get insights into the GF Value metric and future stock price forecasts.
Y-mAbs Therapeutics (YMAB) recently experienced a notable downturn, with shares dropping approximately 6%. This decline followed a downgrade by Bank of America to an "Underperform" rating. The downgrade was primarily attributed to the perceived limited growth potential of its key drug, Danyelza. Analysts highlighted a downward trend in U.S. sales and predicted that international sales might not compensate sufficiently in the upcoming year.
Wall Street Analysts Forecast
Despite current challenges, optimism remains among analysts regarding Y-mAbs Therapeutics Inc (YMAB). According to projections from 11 financial analysts, the average price target stands at $16.64, with estimates ranging between a high of $26.00 and a low of $7.00. Notably, this average target suggests an impressive upside potential of 327.82% from the existing stock price of $3.89. For further details, please visit the Y-mAbs Therapeutics Inc (YMAB, Financial) Forecast page.
The consensus recommendation among brokerage firms positions Y-mAbs Therapeutics Inc (YMAB) with an average rating of 2.0, which corresponds to an "Outperform" status. The recommendation scale spans from 1 to 5, where 1 signifies a Strong Buy and 5 indicates a Sell.
Understanding the GF Value
Investors can also consider the GF Value estimate for Y-mAbs Therapeutics Inc (YMAB), which stands at $11.73 for the next year. This estimation projects a potential upside of 201.65% from the present stock price of $3.8886. The GF Value is GuruFocus' proprietary estimate of the fair market value at which the stock should ideally trade. This figure is derived from the historical market multiples of the stock, past growth performance, and forecasted business developments. More detailed insights can be accessed on the Y-mAbs Therapeutics Inc (YMAB, Financial) Summary page.
